Multiple myeloma (MM), a plasma cell malignancy, is characterised by lesions in multiple bones involving transformed, matured post-follicular B cells. The course of the disease involves an initial development of monoclonal gammopathy of undetermined significance (MGUS), followed by smouldering MM, before the full MM disease emerges. Despite novel therapies, MM remains incurable, managed by combination therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-human CD38 (daratumumab). MM patients have an increased risk of thromboembolic events due to combination treatments with IMiDs, PIs and anti-human CD38 antibody, and steroids. This review will examine the efficacy and pro-thrombotic effects of MM therapies.

中文翻译：

---

用于治疗多发性骨髓瘤的新一代药物。

多发性骨髓瘤（MM）是浆细胞恶性肿瘤，其特征是涉及转化的，成熟的滤泡后B细胞的多个骨骼中的病变。该病的病程涉及具有重要意义的单克隆性丙种球蛋白病（MGUS）的初步发展，然后在完全的MM病出现之前，闷烧MM。尽管有新颖的疗法，但MM仍然无法治愈，可以通过包括蛋白酶体抑制剂（PIs），免疫调节剂（IMiDs）和抗人CD38（daratumumab）在内的联合疗法进行治疗。由于使用IMiD，PI和抗人CD38抗体以及类固醇的联合治疗，MM患者发生血栓栓塞事件的风险增加。这项审查将检查MM疗法的功效和促血栓形成作用。